Clinical trials2019-07-08T16:42:47+01:00

Clinical Trials

According to the International Clinical Trials Registry Platform under the World Health Organization (WHO) and under the U.S. National Institutes of Health the following trials should be recruiting at this moment:

  • A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of Cinryze (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With HAE – recruiting in Argentina, Germany, Italy, Mexico, Romania, the United Kingdom, the United States of America
  • A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with HAE – recruiting in Japan
  • A Long Term Safety Study of BCX7353 in HAE – recruiting in Australia, Austria, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, South Korea, North Macedonia, New Zealand, Poland, Serbia, Slovakia, South Africa, Spain, Switzerland, the United Kingdom
  • A Study to Investigate CSL312 in Subjects With HAE – recruiting in Australia, Canada, Germany, Israel, and the United States of America
  • Biomarker for HAE Type 1 (BioHAE) – recruiting in Egypt, Georgia, Germany, India
  • C1 Inhibitor Registry in the Treatment of HAE Attacks – recruiting in Bulgaria, Croatia, Czech Republic, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, Sweden
  • Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population – recruiting in France
  • Epidemiological Analysis for HAE – recruiting in Germany, Poland, Turkey, the United Kingdom
  • Firazyr Patient Registry (Icatibant Outcome Survey – IOS) – recruiting in Australia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Spain, Sweden, the United Kingdom
  • Global Registry to Gather Data on Natural History of Patients With HAE Type I and II – recruiting in Italy
  • Pathophysiological study for autoimmune dysregulation of HAE – recruiting in Japan
  • Patient Registry to Evaluate the Real-world Safety of Ruconest – recruiting in the United States of America
  • Study of BCX7353 as a Treatment for Attacks of HAE – recruiting in Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Romania, Switzerland, the United Kingdom
  • Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan – recruiting in Japan
  • Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With HAE – will be recruiting in the United States of America
  • The Role of the Coagulation Pathways in Recurrent Angioedema – recruiting in France

Read more about these and other clinical trials at and

HAE related topics that might interest you

Global Access Program

Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program

Global Perspectives

Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community

HAEi Connect Member database

Free, secure online membership database and communications platform for HAEi’s member organizations

Regional Patient Advocates

Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized

Stay tuned – sign up for our newsletter


Click here to sign up

HAE Global Conference 2018

This 4th HAE conference was record breaking: A total of 736 patients and care givers participated from no less than 57 countries

HAEi hosted websites

Hosting of your national website or help for you to create a new website – naturally all in your native language